Projects

Projects

The project cost ₹ 7.7 million (INR).
The goal of the proposed project is to develop a tumor necrosis factor alpha (TNF-α) inhibiting first-in-class, orally bioavailable anti-neuroinflammatory small molecule drug treatment for neurocognitive dysfunction. The primary disease indication for our TNF-α inhibiting thionylated thalidomide compounds (thiothalidomides) is Alzheimer's disease (AD).
The project cost ₹ 3.6 million (INR).
The project deals with the innovative skin patch as transdermal delivery system in treatment and management of Rheumatoid Arthritis.
The project cost ₹ 6.0 million (INR).
The proposed study aims to develop a rapid point-of-care (POC) prognosticative assay device which will provide clinically actionable predictive data indicating the impending onset of delayed high intracranial pressure (HICP) after a severe traumatic brain injury (sTBI).
The project cost ₹ 0.8 million (INR).
The project is to rule out safety & tolerability of the novel adjuvant as this vaccine is administered to healthy individuals including infants and children.